These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 736743)

  • 1. Rationale of chemotherapeutic adjuvant treatment.
    Goldin A
    Arch Geschwulstforsch; 1978; 48(7):627-35. PubMed ID: 736743
    [No Abstract]   [Full Text] [Related]  

  • 2. Sequential administration of two oncostatic drugs: study of modalities for pharmacodynamic potentiation.
    Pouillart R; Huong TH; Brugerie E; Lheritier J
    Biomedicine; 1974 Dec; 21(12):471-9. PubMed ID: 4462870
    [No Abstract]   [Full Text] [Related]  

  • 3. Combined therapy of L1210 leukemia with Damvar and cytostatics.
    Pujman V; Cernochová S
    Neoplasma; 1979; 26(5):521-3. PubMed ID: 522924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of tests of chemotherapeutic agents involving repeated drug treatment.
    Ullman NS; Jacquez JA
    Biometrics; 1973 Dec; 29(4):677-93. PubMed ID: 4785233
    [No Abstract]   [Full Text] [Related]  

  • 5. Combination chemotherapy in sequence for the treatment of L1210 leukemia.
    Roberts D; Hilliard SL
    Cancer Res; 1978 Aug; 38(8):2317-20. PubMed ID: 667827
    [No Abstract]   [Full Text] [Related]  

  • 6. Basis of observed resistance of L1210 leukemia in mice: methotrexate, 6-thioguanine, 6-methylmercaptopurine riboside, 6-mercaptopurine, 5-fluorouracil, and 1-beta-D-arabinofuranosylcytosine administered in different combinations.
    Kim K; Blechman WJ; Riddle VG; Pardee AB
    Cancer Res; 1981 Nov; 41(11 Pt 1):4529-34. PubMed ID: 7198006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An assessment of massive-dose chemotherapy of malignant disease.
    Bergsagel DE
    Can Med Assoc J; 1971 Jan; 104(1):31-6. PubMed ID: 4322068
    [No Abstract]   [Full Text] [Related]  

  • 8. Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules.
    Skipper HE; Schabel FM; Mellett LB; Montgomery JA; Wilkoff LJ; Lloyd HH; Brockman RW
    Cancer Chemother Rep; 1970 Dec; 54(6):431-50. PubMed ID: 5527023
    [No Abstract]   [Full Text] [Related]  

  • 9. [L 1210 leukemia, an experimental model for the potentiation of drugs used for acute leukemias].
    Pouillart P; Huong TH; Lhéritier J
    Bull Cancer; 1974; 61(4):509-26. PubMed ID: 4458834
    [No Abstract]   [Full Text] [Related]  

  • 10. Cancer chemotherapy today and tomorrow. (A review).
    Shetty PA
    Indian J Cancer; 1971 Mar; 8(1):72-5. PubMed ID: 4934495
    [No Abstract]   [Full Text] [Related]  

  • 11. Factors pertaining to complete drug-induced remission of tumor in animals and man.
    Goldin A
    Cancer Res; 1969 Dec; 29(12):2285-91. PubMed ID: 4917976
    [No Abstract]   [Full Text] [Related]  

  • 12. Chemotherapy of hormonally unresponsive prostatic carcinoma.
    deKernion JB; Lindner A
    Urol Clin North Am; 1984 May; 11(2):319-26. PubMed ID: 6233779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple combination therapy in cancer chemotherapy in Japan.
    Ota K
    Gan; 1969 Jun; 60(3):239-46. PubMed ID: 4981311
    [No Abstract]   [Full Text] [Related]  

  • 14. Single versus combination chemotherapy of L1210 leukemia.
    Koza I; Balázová E; Ujházy V
    Neoplasma; 1980; 27(6):691-6. PubMed ID: 7254424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of antileukemic agents in advanced leukemia L1210 in mice. IX.
    Kline I; Gang M; Tyrer DD; Venditti JM; Artis EW; Goldin A
    Cancer Chemother Rep 2; 1971 Apr; 2(1):65-133. PubMed ID: 5565539
    [No Abstract]   [Full Text] [Related]  

  • 16. Characteristics and response to certain cancer chemotherapeutic agents of an acute lymphocytic leukemia arising in a BALB-c times DBA-2F1 mouse.
    Yancey ST; Bleyer WA
    Cancer Res; 1974 Aug; 34(8):1866-9. PubMed ID: 4526157
    [No Abstract]   [Full Text] [Related]  

  • 17. [Chemotherapy of L1210 leukemia: comparison of 7 drugs given either continuously for 20 days, or in a single massive dose, early or late].
    Mathé G; Schwarzenberg L; Hayat M; Schneider M
    Rev Fr Etud Clin Biol; 1968 Dec; 13(10):951-60. PubMed ID: 5306738
    [No Abstract]   [Full Text] [Related]  

  • 18. The antileukemic effectiveness of 5-fluorouracil and methotrexate in the combination chemotherapy of advanced leukemia L1210 in mice.
    Kline I; Venditti JM; Mead JA; Tyrer DD; Goldin A
    Cancer Res; 1966 May; 26(5):848-52. PubMed ID: 5934795
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of advanced breast cancer with 2 successive chemotherapeutic schedules].
    Pérez JE; Machiavelli M; Romero A; Leone BA; Rabinovich MG; Arévalo E
    Medicina (B Aires); 1982; 42(6 Pt 1):587-95. PubMed ID: 6897849
    [No Abstract]   [Full Text] [Related]  

  • 20. Synergistic effects of bis(3-methylsulfonyloxypropyl)-amine toluenesulfonate (864-T) with 6-mercaptopurine and other antitumor agents.
    Imamura H; Ikegami K; Okumoto T
    Gan; 1973 Oct; 64(5):427-31. PubMed ID: 4358730
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.